Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1075463 | 0.88 | POLB (0.41) | POLBPIK3CAGRM5GRM1KDM4E | |
| SCHEMBL1072687 | 0.88 | PDE2A (0.40) | POLBPIK3CANPC1CASP3RAB9A | |
| SCHEMBL1074623 | 0.87 | PIK3CA (0.41) | POLBPIK3CAGRM1KDM4E | |
| SCHEMBL1902279 | 0.86 | CYP1A2 (0.39) | POLBPIK3CANPC1CASP3RAB9A | |
| SCHEMBL1074169 | 0.85 | NPC1 (0.41) | NPC1CASP3RAB9ASENP8SENP7 | |
| SCHEMBL1073735 | 0.82 | SMN1; SMN2 (0.41) | POLBPIK3CAKDM4E | |
| SCHEMBL1076165 | 0.81 | POLB (0.36) | POLBPIK3CAGRM5GRM1KDM4E | |
| SCHEMBL1073760 | 0.81 | POLB (0.36) | POLBKDM4E | |
| SCHEMBL1074860 | 0.80 | POLB (0.36) | POLBPIK3CAGRM5GRM1KDM4E | |
| SCHEMBL1082336 | 0.79 | PDE2A (0.40) | POLBPIK3CANPC1CASP3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110045101-A1 | FUNGICIDAL SUBSTITUTED AZOLES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-02-24 | — | — | US | claimed |
| EP-2274284-A2 | FUNGICIDAL SUBSTITUTED AZOLES | E. I. Du Pont de Nemours and Company (US) | 2011-01-19 | — | — | EP | claimed |
| WO-2009137538-A2 | FUNGICIDAL SUBSTITUTED AZOLES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-11-12 | — | — | WO | claimed |
| WO-2009137651-A2 | FUNGICIDAL SUBSTITUTED AZOLES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-11-12 | — | — | WO | claimed |
| WO-2018048969-A1 | MULTI-TARGETED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2011056463-A2 | FUNGICIDAL MIXTURES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110045101-A1 | FUNGICIDAL SUBSTITUTED AZOLES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-02-24 | — | — | US | disclosed |
| EP-2274284-A2 | FUNGICIDAL SUBSTITUTED AZOLES | E. I. Du Pont de Nemours and Company (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009137538-A2 | FUNGICIDAL SUBSTITUTED AZOLES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137651-A2 | FUNGICIDAL SUBSTITUTED AZOLES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110045101-A1 | FUNGICIDAL SUBSTITUTED AZOLES | CBR3, NOX3, CBR1 | POLB 4699/4885PIK3CA 528/4885NPC1 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.